Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00274573
First received: January 9, 2006
Last updated: November 20, 2013
Last verified: November 2013
  Purpose

The primary objective of this study is to investigate the effect of tiotropium vs. placebo on trough FEV1 and FEV1 2 hours post inhalation after 12 weeks of treatment. For both endpoints changes from baseline will be analysed. Three strata of patients will be included (severe COPD, i.e. <35% of predicted FEV1, moderate COPD, i.e. 35% - <50% of predicted FEV1, mild COPD, i.e. 50% - 70% of predicted FEV1, according to American Thoracic Society [ATS] criteria). The study is conducted in order to find out for which endpoint tiotropium is different from placebo in which stratum.


Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: Tiotropium bromide
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Acute and Long-term Effects of Once Daily Oral Inhalation of Tiotropium 18 Mcg Dry Powder Inhalation Capsules in a Placebo Controlled Parallel Group Design Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Change from baseline in trough FEV1 (Forced expiratory volume in one second) [ Time Frame: after 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in FEV1 2 hours post inhalation [ Time Frame: after 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from baseline in FEV1 2 hours post inhalation [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Change from baseline in FVC (Forced Vital Capacity) 2 hours post inhalation [ Time Frame: Day 1 and 85 ] [ Designated as safety issue: No ]
  • Change from baseline in IVC (Inspiratory Vital Capacity) 2 hours post inhalation [ Time Frame: Day 1 and 85 ] [ Designated as safety issue: No ]
  • Number of patients having a COPD exacerbation [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Number of patients being hospitalised due to a COPD exacerbation [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Number of COPD exacerbations per patient [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Number hospitalisations due to COPD exacerbations per patient [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Duration of COPD exacerbations per patient [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Duration of hospitalisations due to a COPD exacerbation [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 1639
Study Start Date: March 2002
Primary Completion Date: October 2002 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:

    • Patients must have relatively stable, mild to severe airway obstruction with an FEV1 =<70% of predicted normal and an FEV1/FVC < 70 %.
    • Predicted normal values will be taken from the print-outs of the spirometers. Spirometers have to calibrated according to ECCS.
  2. Male or female patients 40 years of age or older.
  3. Patients must be current or ex-smokers with a smoking history of 10 or more than 10 pack-years. Pack Years = Number of cigarettes/day : 20 x years of smoking (Patients who have never smoked cigarettes must not be included)
  4. Patients must be able to perform all study related tests, acceptable pulmonary function tests, including Peak Expiratory Flow Rate (PEFR) measurements, and must be able to maintain diary cards during the study period as required in the protocol.
  5. Patients must be able to inhale medication from the HandiHaler.
  6. All patients must sign an Informed Consent Form prior to participation in the trial i.e. prior to pre-study washout of their usual pulmonary medications.

Exclusion Criteria:

  1. Patients with significant diseases other than COPD will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study.
  2. Patients with a recent history (i.e., one year or less) of myocardial infarction.
  3. Patients with any cardiac arrhythmia requiring drug therapy or who have been hospitalised for heart failure within the past three years.
  4. Patients who regularly use daytime oxygen therapy for more than 1 hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy.
  5. Patients with known active tuberculosis.
  6. Patients with a history of cancer within the last five years. Patients with treated basal cell carcinoma are allowed.
  7. Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis.
  8. Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion 1.
  9. Patients with any respiratory infection in the past six weeks prior to the Screening Visit (Visit 1) or during the run-in period.
  10. Patients who are currently in a pulmonary rehabilitation programme or who have completed a pulmonary rehabilitation programme in the six week prior to the Screening Visit (Visit 1).
  11. Patients with known hypersensitivity to anticholinergic drugs, lactose or any other components of the inhalation capsule delivery system.
  12. Patients with known symptomatic prostate hypertrophy or bladder neck obstruction.
  13. Patients with known narrow-angle glaucoma.
  14. Patients using oral corticosteroid medication at unstable doses (i.e., less than four weeks on a stable dose before Visit 1) or at doses in excess of the equivalent of 10 mg of prednisolone per day or 20 mg every other day.
  15. Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e. oral contraceptives, intrauterine devices, diaphragm or subdermal implants).
  16. Patients with a history of asthma, allergic rhinitis or atopy.
  17. Patients with a history of and/or active significant alcohol or drug abuse.
  18. Patients who have taken an investigational drug within one month prior to Screening Visit (Visit 1). A log of all subjects screened, and reasons for exclusion for those not randomised will be maintained.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00274573

  Hide Study Locations
Locations
Germany
Boehringer Ingelheim Investigational Site
Aachen, Germany
Boehringer Ingelheim Investigational Site
Ahrensburg, Germany
Boehringer Ingelheim Investigational Site
Altenburg, Germany
Boehringer Ingelheim Investigational Site
Amberg, Germany
Boehringer Ingelheim Investigational Site
Aschaffenburg, Germany
Boehringer Ingelheim Investigational Site
Aue, Germany
Boehringer Ingelheim Investigational Site
Auerbach, Germany
Boehringer Ingelheim Investigational Site
Augsburg, Germany
Boehringer Ingelheim Investigational Site
Backnang, Germany
Boehringer Ingelheim Investigational Site
Bad Kissingen, Germany
Boehringer Ingelheim Investigational Site
Bad Krozingen, Germany
Boehringer Ingelheim Investigational Site
Bad Lippspringe, Germany
Boehringer Ingelheim Investigational Site
Bad Nauheim, Germany
Boehringer Ingelheim Investigational Site
Bad Neustadt, Germany
Boehringer Ingelheim Investigational Site
Bad Soden, Germany
Boehringer Ingelheim Investigational Site
Baunatal, Germany
Boehringer Ingelheim Investigational Site
Beckum, Germany
Boehringer Ingelheim Investigational Site
Bensheim, Germany
Boehringer Ingelheim Investigational Site
Berlin, Germany
MEDARS GmbH
Berlin, Germany
Boehringer Ingelheim Investigational Site
Bernau, Germany
Boehringer Ingelheim Investigational Site
Bielefeld, Germany
Boehringer Ingelheim Investigational Site
Bochum, Germany
Boehringer Ingelheim Investigational Site
Bonn, Germany
Boehringer Ingelheim Investigational Site
Brake, Germany
Boehringer Ingelheim Investigational Site
Brandenburg, Germany
Boehringer Ingelheim Investigational Site
Braunschweig, Germany
Boehringer Ingelheim Investigational Site
Bruchsal, Germany
Boehringer Ingelheim Investigational Site
Buchholz, Germany
Boehringer Ingelheim Investigational Site
Celle, Germany
Boehringer Ingelheim Investigational Site
Chemnitz, Germany
Boehringer Ingelheim Investigational Site
Cloppenburg, Germany
Boehringer Ingelheim Investigational Site
Coburg, Germany
Boehringer Ingelheim Investigational Site
Dachau, Germany
Boehringer Ingelheim Investigational Site
Darmstadt, Germany
Boehringer Ingelheim Investigational Site
Deggendorf, Germany
Boehringer Ingelheim Investigational Site
Delmenhorst, Germany
Boehringer Ingelheim Investigational Site
Detmold, Germany
Boehringer Ingelheim Investigational Site
Dillingen, Germany
Boehringer Ingelheim Investigational Site
Dinslaken, Germany
Boehringer Ingelheim Investigational Site
Dortmund, Germany
Boehringer Ingelheim Investigational Site
Dresden, Germany
Boehringer Ingelheim Investigational Site
Duisburg, Germany
Boehringer Ingelheim Investigational Site
Dülmen, Germany
Boehringer Ingelheim Investigational Site
Düren, Germany
Boehringer Ingelheim Investigational Site
Düsseldorf, Germany
Boehringer Ingelheim Investigational Site
Eggenfelden, Germany
Boehringer Ingelheim Investigational Site
Eisenach, Germany
Boehringer Ingelheim Investigational Site
Eisenhüttenstadt, Germany
Boehringer Ingelheim Investigational Site
Emden, Germany
Boehringer Ingelheim Investigational Site
Erfurt, Germany
Boehringer Ingelheim Investigational Site
Erlangen, Germany
Boehringer Ingelheim Investigational Site
Essen, Germany
Boehringer Ingelheim Investigational Site
Euskirchen, Germany
Boehringer Ingelheim Investigational Site
Fellbach, Germany
Boehringer Ingelheim Investigational Site
Fluda, Germany
Boehringer Ingelheim Investigational Site
Frankenthal, Germany
Boehringer Ingelheim Investigational Site
Frankfurt, Germany
Boehringer Ingelheim Investigational Site
Frankfurt/Main, Germany
Boehringer Ingelheim Investigational Site
Frankfurt/Oder, Germany
Boehringer Ingelheim Investigational Site
Freising, Germany
Boehringer Ingelheim Investigational Site
Fulda, Germany
Boehringer Ingelheim Investigational Site
Fürstenfeldbruck, Germany
Boehringer Ingelheim Investigational Site
Fürstenwalde, Germany
Boehringer Ingelheim Investigational Site
Fürth, Germany
Boehringer Ingelheim Investigational Site
Garmisch-Partenkirchen, Germany
Boehringer Ingelheim Investigational Site
Gelsenkirchen, Germany
Boehringer Ingelheim Investigational Site
Germering, Germany
Boehringer Ingelheim Investigational Site
Goch, Germany
Boehringer Ingelheim Investigational Site
Greiz, Germany
Boehringer Ingelheim Investigational Site
Groß Gaglow, Germany
Boehringer Ingelheim Investigational Site
Großenhain, Germany
Boehringer Ingelheim Investigational Site
Göppingen, Germany
Boehringer Ingelheim Investigational Site
Gütersloh, Germany
Boehringer Ingelheim Investigational Site
Hagen, Germany
Boehringer Ingelheim Investigational Site
Hamburg, Germany
Boehringer Ingelheim Investigational Site
Hamm, Germany
Boehringer Ingelheim Investigational Site
Hannover, Germany
Boehringer Ingelheim Investigational Site
Hartha, Germany
Boehringer Ingelheim Investigational Site
Heidelberg, Germany
Boehringer Ingelheim Investigational Site
Heidenheim, Germany
Boehringer Ingelheim Investigational Site
Heilbronn, Germany
Boehringer Ingelheim Investigational Site
Hemmingen, Germany
Boehringer Ingelheim Investigational Site
Hildburghausen, Germany
Boehringer Ingelheim Investigational Site
Hildesheim, Germany
Boehringer Ingelheim Investigational Site
Homburg/Saar, Germany
Boehringer Ingelheim Investigational Site
Hoyerswerda, Germany
Boehringer Ingelheim Investigational Site
Ingolstadt, Germany
Boehringer Ingelheim Investigational Site
Kamen, Germany
Boehringer Ingelheim Investigational Site
Karlsruhe, Germany
Boehringer Ingelheim Investigational Site
Kaufbeuren, Germany
Boehringer Ingelheim Investigational Site
Kempten, Germany
Boehringer Ingelheim Investigational Site
Kiel, Germany
Boehringer Ingelheim Investigational Site
Koblenz, Germany
Boehringer Ingelheim Investigational Site
Krefeld, Germany
Boehringer Ingelheim Investigational Site
Köln, Germany
Boehringer Ingelheim Investigational Site
Köthen, Germany
Boehringer Ingelheim Investigational Site
Landshut, Germany
Boehringer Ingelheim Investigational Site
Langenhagen, Germany
Boehringer Ingelheim Investigational Site
Leipzig, Germany
Boehringer Ingelheim Investigational Site
Leonberg, Germany
Boehringer Ingelheim Investigational Site
Ludwigsburg, Germany
Boehringer Ingelheim Investigational Site
Lörrach, Germany
Boehringer Ingelheim Investigational Site
Lübeck, Germany
Boehringer Ingelheim Investigational Site
Lüdenscheid, Germany
Boehringer Ingelheim Investigational Site
Lüneburg, Germany
Boehringer Ingelheim Investigational Site
Magdeburg, Germany
Boehringer Ingelheim Investigational Site
Mainz, Germany
Johannes-Gutenberg-Universität Mainz
Mainz, Germany
Boehringer Ingelheim Investigational Site
Mannheim, Germany
Boehringer Ingelheim Investigational Site
Marburg, Germany
Boehringer Ingelheim Investigational Site
Markkleeberg, Germany
Boehringer Ingelheim Investigational Site
Minden, Germany
Boehringer Ingelheim Investigational Site
Mittweida, Germany
Boehringer Ingelheim Investigational Site
Moers, Germany
Boehringer Ingelheim Investigational Site
Mönchengladbach, Germany
Boehringer Ingelheim Investigational Site
Mühlhausen, Germany
Boehringer Ingelheim Investigational Site
München, Germany
Boehringer Ingelheim Investigational Site
Münster, Germany
Boehringer Ingelheim Investigational Site
Neu-Isenburg, Germany
Boehringer Ingelheim Investigational Site
Neu-Ulm, Germany
Boehringer Ingelheim Investigational Site
Neubrandenburg, Germany
Boehringer Ingelheim Investigational Site
Neuss, Germany
Boehringer Ingelheim Investigational Site
Neuwied, Germany
Boehringer Ingelheim Investigational Site
Niesky, Germany
Boehringer Ingelheim Investigational Site
Nordhausen, Germany
Boehringer Ingelheim Investigational Site
Nortorf, Germany
Boehringer Ingelheim Investigational Site
Oschatz, Germany
Boehringer Ingelheim Investigational Site
Oschersleben, Germany
Boehringer Ingelheim Investigational Site
Papenburg, Germany
Boehringer Ingelheim Investigational Site
Potsdam, Germany
Boehringer Ingelheim Investigational Site
Rathenow, Germany
Boehringer Ingelheim Investigational Site
Recklinghausen, Germany
Boehringer Ingelheim Investigational Site
Regensburg, Germany
Boehringer Ingelheim Investigational Site
Rehau, Germany
Boehringer Ingelheim Investigational Site
Remscheid, Germany
Boehringer Ingelheim Investigational Site
Reutlingen, Germany
Boehringer Ingelheim Investigational Site
Rhaunen, Germany
Boehringer Ingelheim Investigational Site
Rostock, Germany
Boehringer Ingelheim Investigational Site
Rüdersdorf, Germany
Boehringer Ingelheim Investigational Site
Rüsselsheim, Germany
Boehringer Ingelheim Investigational Site
Saarbrücken, Germany
Boehringer Ingelheim Investigational Site
Saarlouis, Germany
Boehringer Ingelheim Investigational Site
Schrobenhausen, Germany
Boehringer Ingelheim Investigational Site
Schwabach, Germany
Boehringer Ingelheim Investigational Site
Schweinfurt, Germany
Boehringer Ingelheim Investigational Site
Schwetzingen, Germany
Boehringer Ingelheim Investigational Site
Schwäbisch Gmünd, Germany
Boehringer Ingelheim Investigational Site
Siegen, Germany
Boehringer Ingelheim Investigational Site
Simmern, Germany
Boehringer Ingelheim Investigational Site
Sindelfingen, Germany
Boehringer Ingelheim Investigational Site
Singen, Germany
Boehringer Ingelheim Investigational Site
Solingen, Germany
Boehringer Ingelheim Investigational Site
Sonneberg, Germany
Boehringer Ingelheim Investigational Site
St. Ingbert, Germany
Boehringer Ingelheim Investigational Site
Stade, Germany
Boehringer Ingelheim Investigational Site
Steinhagen, Germany
Boehringer Ingelheim Investigational Site
Stolberg, Germany
Boehringer Ingelheim Investigational Site
Stuttgart, Germany
Boehringer Ingelheim Investigational Site
Teuchern, Germany
Boehringer Ingelheim Investigational Site
Ulm, Germany
Boehringer Ingelheim Investigational Site
Uttenreuth, Germany
Boehringer Ingelheim Investigational Site
Vechta, Germany
Boehringer Ingelheim Investigational Site
Velbert, Germany
Boehringer Ingelheim Investigational Site
Verden, Germany
Boehringer Ingelheim Investigational Site
Vöhringen, Germany
Boehringer Ingelheim Investigational Site
Waiblingen, Germany
Boehringer Ingelheim Investigational Site
Waren, Germany
Boehringer Ingelheim Investigational Site
Welzheim, Germany
Boehringer Ingelheim Investigational Site
Weyhe, Germany
Boehringer Ingelheim Investigational Site
Wiesbaden, Germany
Boehringer Ingelheim Investigational Site
Wiesloch, Germany
Boehringer Ingelheim Investigational Site
Witten, Germany
Boehringer Ingelheim Investigational Site
Wolfsburg, Germany
Boehringer Ingelheim Investigational Site
Wuppertal, Germany
Boehringer Ingelheim Investigational Site
Zerbst, Germany
Boehringer Ingelheim Investigational Site
Zwickau, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Study Coordinator Boehringer Ingelheim KG
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00274573     History of Changes
Other Study ID Numbers: 205.257
Study First Received: January 9, 2006
Last Updated: November 20, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
United States: Food and Drug Administration

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases
Tiotropium
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 21, 2014